Key result
Advanced liver fibrosis linked to ~291% greater risk of AF recurrence after ablation.
Why the study?
Advanced liver fibrosis is linked to new-onset AF, but its association with AF recurrence after ablation in patients with NAFLD remained to be investigated.
Do intermediate and high non-invasive liver fibrosis scores (NFS and FIB-4) predict atrial fibrillation recurrence after ablation in patients with non-alcoholic fatty liver disease?
Population
345 AF patients with NAFLD undergoing de novo ablation at two hospitals in China
Comparison
Intermediate and high vs low NFS and FIB-4 risk categories
Design
Two-centre observational study
Follow-up
1 year
Authors
Loading...
May support fibrosis scoring for post-ablation AF recurrence risk in NAFLD; hypothesis-generating pending prospective validation.
Cohort (n=345)
Yes
Do intermediate and high non-invasive liver fibrosis scores (NFS and FIB-4) predict atrial fibrillation recurrence after ablation in patients with non-alcoholic fatty liver disease?
Hazard Ratio: 3.91 (95% CI 2.19–6.98)
Absolute Event Rate: 60% vs 20.4%
p-value: p=<0.001
In patients with NAFLD undergoing atrial fibrillation ablation, advanced liver fibrosis assessed by non-invasive scores (NFS and FIB-4) is strongly associated with an increased risk of AF recurrence.
Wang et al. (2022) conducted a cohort in Atrial fibrillation with non-alcoholic fatty liver disease (n=345). Advanced liver fibrosis (high FIB-4 score) vs. Low risk of advanced liver fibrosis (low FIB-4 score) was evaluated on Atrial fibrillation recurrence (atrial arrhythmia >30s after 3-month blanking period) (HR 3.91, 95% CI 2.19-6.98, p=<0.001). Advanced liver fibrosis, indicated by a high FIB-4 score, was independently associated with a significantly increased risk of atrial fibrillation recurrence after ablation (HR 3.91).